Adempas

Χώρα: Νέα Ζηλανδία

Γλώσσα: Αγγλικά

Πηγή: Medsafe (Medicines Safety Authority)

Δραστική ουσία:

Riociguat 2.5mg

Διαθέσιμο από:

Bayer New Zealand Limited

INN (Διεθνής Όνομα):

Riociguat 2.5 mg

Δοσολογία:

2.5 mg

Φαρμακοτεχνική μορφή:

Film coated tablet

Σύνθεση:

Active: Riociguat 2.5mg Excipient: Crospovidone Hyprolose Hypromellose   Iron oxide red Iron oxide yellow Lactose monohydrate Magnesium stearate Microcrystalline cellulose Propylene glycol Purified water Sodium laurilsulfate Titanium dioxide

Τρόπος διάθεσης:

Prescription

Κατασκευάζεται από:

Bayer AG

Θεραπευτικές ενδείξεις:

Pulmonary arterial hypertension Adempas, as monotherapy or in combination with approved PAH treatments (endothelin receptor agonists or inhaled or subcutaneous prostanoids ), is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - heritable pulmonary arterial hypertension - pulmonary arterial hypertension associated with connective tissue diseases - pulmonary arterial hypertension associated with congenital heart disease in adult patients with WHO functional Class II, III or IV symptoms.

Περίληψη προϊόντος:

Package - Contents - Shelf Life: Blister pack, PP/Al - 42 tablets - 36 months from date of manufacture stored at or below 30°C - Blister pack, PP/Al - 84 tablets - 36 months from date of manufacture stored at or below 30°C

Ημερομηνία της άδειας:

2014-06-25